We use first- and third-party cookies to provide our services and collect statistical data. By continuing to browse you accept these cookies. More information Accept
About us
CNS pharmaceuticals

Our vision

To be the European leader in pharmaceutical products for
the treatment of the central nervous system (CNS)

Our mission

To offer a wide range of proven, differentiated and affordable
CNS treatment options to patients, healthcare professionals and industry partners 
– based on our in-depth knowledge of the differentiated CNS markets in the different European countries

With a unique understanding of the CNS market for over 30 years, Neuraxpharm develops and commercializes value added medicines, standard generics and Consumer Healthcare products, e.g. nutraceuticals and probiotics in Europe.

We are continuously striving to offer a wide range of effective, high quality and affordable CNS treatments aimed at patients as well as health professionals and industry partners.

Additionally, through our manufacturing companies Lesvi and Inke, Neuraxpharm has an international presence in over 50 countries. We provide industry partners with finished dosage forms (FDFs) across multiple technologies and niche active pharmaceutical ingredients (APIs) using our expertise in the CNS and the respiratory areas.


Specialised
in CNS
since 1985

Neuraxpharm company

OUR STRATEGIC PRINCIPLES

  • leader in CNS

    Market Presence
    with sales forces in our main EU markets to strengthen our international position as a leader in CNS

  • CNS R&D Investment

    R&D Investment 
    into a robust pipeline that broadens our CNS portfolio with differentiated products

  • CNS patients and healthcare professionals

    Partnership 
    with the European community of CNS patients and healthcare professionals

  • Selling of FDFs and APIs

    Value generation
    from our international portfolio through the B2B selling of FDFs and APIs

  • CNS backward integration

    Synergy 
    via backward integration and strengthening operational excellence within the company

  • CNS backward integration

    Start-up culture
    with a strong focus on quality, collaboration and agility promoting smart solutions that differentiate us from our competitors

BACKWARD INTEGRATION
The consolidation of all the companies within Neuraxpharm allows us to establish growth and cross-business operational synergies in strategic aspects such as R&D, manufacturing, procurement, cross-licensing and geographical expansion

NEURAXPHARM GROUP

Neuraxpharm develops and commercializes branded and generic CNS pharmaceuticals and nutraceuticals for the treatment and prevention of CNS disorders in main European countries

Neuraxpharm also owns and operates two manufacturing plants in Spain

  • Laboratorios Lesvi

    B2B solutions provider dedicated to the development and manufacturing of finished dosage forms (FDFs)

    More
  • Inke

    Focused on the development and manufacturing of the highest quality active pharmaceutical ingredients (APIs) with complex synthesis processes

    More
First partner of choice in CNS

NEURAXPHARM

is your first partner of choice in CNS
More
Neuraxpharm turnover

350M€ Turnover

central nervous system
>130
CNS MOLECULES
MOLECULES IN CNS >70%
EUROPEAN CNS MARKET REACHED WITH OWN PRESENCE
EUROPEAN CNS MARKET REACHED WITH OWN PRESENCE >750
group employees
APIs and FDF 40%
SALES & MARKETING EMPLOYEES
CNS R&D 20%
R&D SPECIALISTS

Selling APIs and FDFs to more than 50 countries

Global presence

Global presence through selling APIs and FDFs to more than 50 countries

Global CNS company
Neuraxpharm worldwide

VERTICALLY INTEGRATED VALUE CHAIN

Neuraxpharm is vertically integrated from Development to Marketing & Sales activities
Neuraxpharm is vertically integrated from Development to Marketing & Sales activities